Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
暂无分享,去创建一个
Charles C Wykoff | SriniVas R Sadda | Nizar Saleh Abdelfattah | S. Sadda | C. Wykoff | David M. Brown | N. Abdelfattah | David M Brown | J. Payne | Lloyd Clark | Daniel E Croft | Rui Wang | John F Payne | Rui Wang | Daniel E. Croft | Lloyd Clark
[1] Philip J Rosenfeld,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.
[2] R. Guymer,et al. ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION: A Treat-and-Extend Protocol Over 2 Years , 2014, Retina.
[3] S. Chow,et al. Sample Size Calculations In Clinical Research , 2007 .
[4] C. Wykoff,et al. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. , 2013, Ophthalmology.
[5] C. Regillo,et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.
[6] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[7] Allen C Ho,et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.
[8] H. Shapiro,et al. ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2013, Retina.
[9] B. Kirchhof,et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. , 2013, American journal of ophthalmology.
[10] P. Rosenfeld,et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.
[11] P. Ng,et al. A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION , 2013, Retina.
[12] B. Kirchhof,et al. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. , 2012, Ophthalmology.
[13] I. Mantel,et al. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.
[14] J. Slakter,et al. Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) , 2012, Eye.
[15] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[16] Frederick L Ferris,et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. , 2009, Archives of ophthalmology.
[17] C. Regillo,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.
[18] Glenn J Jaffe,et al. Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. , 2011, Investigative ophthalmology & visual science.
[19] Christian Simader,et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.
[20] R. Spaide. Ranibizumab according to need: a treatment for age-related macular degeneration. , 2007, American journal of ophthalmology.
[21] Terje R Pedersen,et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. , 2015, Ophthalmology.
[22] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[23] P. Jong. Prevalence of age-related macular degeneration in the United States. , 2004 .
[24] U. Schmidt-Erfurth,et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.
[25] R. Guymer,et al. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. , 2015, Ophthalmology.
[26] Glenn J Jaffe,et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.
[27] C. Wykoff,et al. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. , 2013, Ophthalmic surgery, lasers & imaging retina.